Zydus Lifesciences Limited
ZYDUSLIFE.NS
₹1156.90
▲ 3.29%
Zydus Lifesciences was the standout gainer on the list, climbing 3.29% to ₹1156.90 even though no specific news was flagged for the move. The pharma name has been a consistent long-term performer, delivering a 14.63% CAGR over one year, 15.86% over five years and 11.72% over a decade, making it one of the steadier compounders among today's movers. A broad panel of 30 analysts has a hold consensus on the stock, with the average target of ₹1195.78 sitting just marginally above today's closing price.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| 9.15% | 1.18% | 15.15% | 11.23% |
Analyst Consensus
Average Target Price: ₹1195.78 (range ₹800.00 - ₹1457.48) based on 30 analysts
Strong Buy: 7
Buy: 8
Hold: 8
Sell: 3
Strong Sell: 4
Related News
| Aug 29, 2026 | Zydus Lifesciences Limited Share Price Jumps 2.11% (Aug 27, 2026) |
| Aug 11, 2026 | Zydus Lifesciences Q1 Consol Net Profit 9.4 Billion Rupees |
No comments:
Post a Comment